Lercanidipine
Sponsors
UCB Pharma, University of Aarhus, Università degli Studi dell'Insubria, RECORDATI GROUP, Aarhus University Hospital
Conditions
Chronic Kidney DiseasesEssential HypertensionHIV InfectionsHigh Blood PressureHypertensionMicrovascular AnginaObesity, Morbid
Phase 2
Phase 4
Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine
NCT00564057
Start: 2007-09-30End: 2009-09-30Target: 30Updated: 2007-12-06
Intensive Vasodilator Therapy in Patients With Essential Hypertension
CompletedNCT01180413
Start: 2010-12-31End: 2012-04-30Updated: 2012-04-19
Zainidip in Renal Artery Stenosis
CompletedNCT02594410
Start: 2011-09-30End: 2014-05-31Updated: 2015-11-03
Unknown Phase
Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients
CompletedNCT00160498
Start: 2004-05-31End: 2005-08-31Target: 180Updated: 2008-03-10
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
TerminatedNCT00424801
Start: 2007-01-31End: 2008-12-31Updated: 2009-05-06
Bariatric Surgery and Pharmacokinetics of Lercanidipine
RecruitingNCT03497156
Start: 2016-11-02End: 2026-10-31Target: 12Updated: 2025-06-06
The Role of Skin Sodium Accumulation in Chronic Kidney Disease
RecruitingNCT07020104
Start: 2025-01-07End: 2039-12-01Target: 60Updated: 2025-06-13